{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/scabies/prescribing-information/chlorphenamine-hydroxyzine/","result":{"pageContext":{"chapter":{"id":"87495d38-99d2-59af-ab1b-3701df31a332","slug":"chlorphenamine-hydroxyzine","fullItemName":"Chlorphenamine and hydroxyzine:","depth":2,"htmlHeader":"<!-- begin field e0d20f0c-d9ed-4991-8aa5-f69865f77444 --><h2>Chlorphenamine and hydroxyzine</h2><!-- end field e0d20f0c-d9ed-4991-8aa5-f69865f77444 -->","summary":"","htmlStringContent":"<!-- begin item 9c65f1de-16e9-481a-ba18-369a57677d95 --><!-- begin field 9a7be28e-4cf3-4f96-975b-12c5624d5c6b --><ul><li><strong>Sedating antihistamines </strong>cause sedation in 10–50% of people, which can persist into the next day [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">DTB, 2002</a>].<ul><li>For more information on the adverse effects of sedating antihistamines, see the section on prescribing information in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/itch-widespread/\">Itch - widespread</a>.</li></ul></li><li><strong>Most non-sedating antihistamines have the potential to cause sedation, </strong>especially at higher doses. Advise people taking non-sedating antihistamines that they may cause sedation, and that the sedative effects are enhanced when combined with alcohol.</li></ul><!-- end field 9a7be28e-4cf3-4f96-975b-12c5624d5c6b --><!-- end item 9c65f1de-16e9-481a-ba18-369a57677d95 -->","topic":{"id":"2239c8be-00a0-56aa-8fe9-0467b238f0c4","topicId":"da2824e2-e1de-4303-9c52-8224034ff953","topicName":"Scabies","slug":"scabies","lastRevised":"Last revised in November 2017","chapters":[{"id":"da8e838e-f347-56db-afd1-75fbd32ad909","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8230d8c6-45b3-5bdb-8cc8-3c1c2b823449","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a4632036-ac3e-5da5-9aff-ee789e83a368","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f3a44b9a-af69-5c7d-9a47-6dc02fafa709","slug":"changes","fullItemName":"Changes"},{"id":"4d9cd925-2e05-5383-933f-f483f2ed7fdc","slug":"update","fullItemName":"Update"}]},{"id":"a65309c1-f446-573c-a812-cd9a67f28cc7","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a68dada3-3034-53ad-9477-23904345690e","slug":"goals","fullItemName":"Goals"},{"id":"bbbd25ab-ead3-5868-b558-5283d76c73ea","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c05af2ff-93bf-5065-acf0-511a278d4cdf","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b592bb65-acf3-54c5-9e50-f1d986ef2099","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6fdf1f82-f5bd-5ebe-b440-d5e2b673f214","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7c704acb-f3b9-5169-b8e6-a401a805fb9f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e967b469-438f-5a3c-b576-bb55b8cd46c0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5119a491-fd63-525d-9787-b77adf1ad31a","slug":"definition","fullItemName":"Definition"},{"id":"d4abdef1-d529-5524-a289-d515c8900234","slug":"prevalence","fullItemName":"Prevalence"},{"id":"8bc35f21-913e-5a50-b011-2b928b93c033","slug":"transmission","fullItemName":"Transmission"},{"id":"1a3cadf7-aa8c-5437-9b8c-ebf6a885e18d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"2065f768-9383-5d5e-8dd5-a0411d51dade","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"783dffe4-5b71-5b67-8b76-aa6d05b04591","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"9fde1af7-a79f-56cf-b595-ac0691f21b5f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"177fab9d-042e-5ed5-bef2-4b96c7157717","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"a4fb57b7-6e89-5bc6-8768-5a2a59312f92","slug":"basis-for-recommendation-501","fullItemName":"Basis for recommendation"}]},{"id":"f0095d1b-7de8-51f8-86f9-51236504dc2c","fullItemName":"Management","slug":"management","subChapters":[{"id":"b8090f99-a407-59d0-bd90-cad808bf8bbf","slug":"management-of-scabies","fullItemName":"Scenario: Management of scabies"}]},{"id":"a3c66bd0-4e63-5096-98e7-3648f3a19fa5","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"82606908-d488-536f-badf-4311c083f9f2","slug":"insecticides","fullItemName":"Insecticides"},{"id":"e0ff263e-9d39-5b6e-a192-b3c23f35b8e2","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"87495d38-99d2-59af-ab1b-3701df31a332","slug":"chlorphenamine-hydroxyzine","fullItemName":"Chlorphenamine and hydroxyzine:"},{"id":"384c43f2-9128-5f2d-92dd-f064f115544a","slug":"crotamiton-10percent-cream","fullItemName":"Crotamiton 10% cream"}]},{"id":"d23e8a1b-527a-5b4e-bc6e-1550c1d7b7f7","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bf5d0fd9-3845-54be-8307-14fee2b8fe46","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"24a603a9-c1be-5619-9cab-6e8cc775ec79","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"862928da-a3ad-5b3c-b1fa-c221c79d2e0a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c1f2f20f-1192-5385-b710-2f4aeb402bc9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"42e0b79b-5cd7-53cd-bc72-422e96a7aaf4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"324db100-c4d0-5d57-9a1f-c8487c474f9e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"860692e0-5ebd-5bb6-8862-8c22738325ca","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a3c66bd0-4e63-5096-98e7-3648f3a19fa5","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"4e3c5fe0-2673-53b6-bad8-442bafc427a4","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field be1b7467-f963-4f04-bbb5-a83c018713c5 --><h3>Contraindications and cautions</h3><!-- end field be1b7467-f963-4f04-bbb5-a83c018713c5 -->","summary":"","htmlStringContent":"<!-- begin item eef18600-1ee1-41d6-abef-a83c01870eda --><!-- begin field b4287959-8620-463a-97e2-a83c018713c5 --><h4>Chlorphenamine</h4><ul><li>Do not prescribe to people who have been treated with MAOIs within the last fourteen days.</li><li>Prescribe with caution to people with:<ul><li>Epilepsy.</li><li>Raised intra-ocular pressure including glaucoma.</li><li>Prostatic hypertrophy.</li><li>Severe hypertension or cardiovascular disease.</li><li>Bronchitis, bronchiectasis, or asthma.</li><li>Hepatic or renal impairment.</li></ul></li><li><strong>Note: </strong>The manufacturer of hydroxyzine states that it should not be used in pregnancy.</li></ul><h4>Hydroxyzine</h4><ul><li>Do not prescribe to people with:<ul><li>Acquired or congenital QT interval prolongation.</li><li>A risk factor for QT interval prolongation including cardiovascular disease, significant electrolyte imbalance (hypokalemia, hypomagnesaemia), family history of sudden cardiac death, significant bradycardia, concomitant use of drugs known to prolong the QT interval and/or induce Torsade de Pointes.</li><li>Asthma, who have previously experienced a serious anti-histamine-induced adverse bronchopulmonary effect.</li><li>Porphyria.</li><li>Severe liver disease.</li></ul></li><li>Prescribe with caution to people with:<ul><li>Hepatic impairment — reduce daily dose by one-third.</li><li>Bradycardia.</li><li>Renal impairment — reduce daily dose by half in moderate to severe renal impairment.</li><li>Increased intraocular pressure/angle-closure glaucoma.</li><li>Urinary retention, prostatic hyperplasia, bladder outflow obstruction.</li><li>Pyroduodenal obstruction.</li><li>Seizure disorders including epilepsy.</li><li>Myasthenia gravis.</li><li>Dementia.</li><li>Decreased GI motility.</li><li>Stenosing peptic ulcer.</li><li>Breathing problems (e.g. emphysema, chronic bronchitis).</li><li>Hyperthyroidism.</li><li>Hypertension or cardiovascular disease.</li><li>Note: Elderly people are particularly susceptible to adverse effects of hydroxyzine. The manufacturer advises to avoid or reduce the dose.</li><li>Caution is also advised in people taking drugs that may induce hypokalaemia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">ABPI, 2016a</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">BNF 74, 2017</a>] </p><!-- end field b4287959-8620-463a-97e2-a83c018713c5 --><!-- end item eef18600-1ee1-41d6-abef-a83c01870eda -->","subChapters":[]},{"id":"c34756cf-edae-5ede-b1e7-0894bdc73e7c","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 2b557c1d-9b2b-4dff-adf1-a83c018a8775 --><h3>Adverse effects</h3><!-- end field 2b557c1d-9b2b-4dff-adf1-a83c018a8775 -->","summary":"","htmlStringContent":"<!-- begin item 585cbde6-a7cc-4dbe-8998-a83c018a83c6 --><!-- begin field 89f80ee9-6d61-40f3-8e8d-a83c018a8775 --><h4>Chlorphenamine</h4><ul><li>The most common adverse effects include blurred vision, dry mouth, gastrointestinal disturbance, headache, psychomotor impairment, and urinary retention.</li><li>Other adverse effects include anaphylaxis, angioedema, angle-closure glaucoma (in adults), arrhythmias, bronchospasm, confusion, convulsions, depression, dizziness, extrapyramidal effects, hypersensitivity reactions, hypotension, liver dysfunction, palpitation, photosensitivity reactions, sleep disturbances, tremor, antimuscarinic effects, blood disorders, exfoliative dermatitis, rashes, tinnitus.<ul><li>Note: Children and elderly people are more likely to experience neurological anticholinergic effects and paradoxical excitation (eg. increased energy, restlessness, nervousness). </li></ul></li></ul><h4>Hydroxyzine</h4><ul><li>The most common adverse effects include dry mouth, fatigue, and headache.</li><li>Other adverse effects include constipation, dizziness, insomnia, nausea, blood disorders, bronchospasm, liver dysfunction, rashes, agitation, alopecia, anorexia, anxiety, blurred vision, coma, confusion, convulsions (with high doses), depression, diarrhoea, drowsiness, extrapyramidal effects, flushing, hallucinations, hypotension, impotence, labyrinthitis, menstrual disturbances, myalgia, palpitation, priapism, psychomotor impairment, sleep disturbance, tachycardia, tinnitus, tremor (with high doses), urinary retention, ventricular arrhythmia, vertigo, vomiting.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">BNF 74, 2017</a>]</p><!-- end field 89f80ee9-6d61-40f3-8e8d-a83c018a8775 --><!-- end item 585cbde6-a7cc-4dbe-8998-a83c018a83c6 -->","subChapters":[]},{"id":"cb05cd2a-ab75-5ebc-a299-c9292143b236","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field e69e352c-cbd1-4b4c-afc2-a83f00db646c --><h3>Drug interactions</h3><!-- end field e69e352c-cbd1-4b4c-afc2-a83f00db646c -->","summary":"","htmlStringContent":"<!-- begin item 73337f47-d373-4dcc-aac4-a83f00db5f82 --><!-- begin field 9d4751fe-b5ed-431c-9437-a83f00db646c --><p><strong>Key drug interactions with chlorphenamine include:</strong></p><ul><li><strong>Hypnotics or anxiolytics</strong> — may increase sedative effects.</li><li><strong>Phenytoin</strong>— chlorphenamine inhibits phenytoin metabolism and can lead to phenytoin toxicity.</li><li><strong>MAOIs</strong> — concomitant use may intensify the anticholinergic effects of chlorphenamine.</li></ul><p><strong>Key drug interactions with hydroxyzine include:</strong></p><ul><li><strong>Drugs known to prolong the QT interval and/or induce Torsade de Pointes</strong>  (such as class IA [e.g. quinidine, disopyramide] and III antiarrhythmics [e.g. amiodarone, sotalol], some antihistamines, some antipsychotics [e.g. haloperidol], some antidepressants [e.g. citalopram, escitalopram], some antimalarial drugs [e.g. mefloquine], some antibiotics [e.g. erythromycin, levofloxacin, moxifloxacin], some antifungal agents [e.g. pentamidine], some gastrointestinal medicines [e.g. prucalopride], some medicines used in cancer [e.g. toremifene, vandetanib], ondansetron) —increase the risk of cardiac arrhythmia.</li><li><strong>CNS depressants </strong>(such as alcohol, barbiturates, benzodiazepines, hypnotics, opioids, anxiolytics, antipsychotics, antidepressants, antiemetics, antiepileptics, other antihistamines, skeletal muscle relaxants, and sedatives — concomitant use enhances CNS depressant effects.</li><li><strong>Antimuscarinics </strong>(such as atropine and some antidepressants [both tricyclics and MAOIs]) — concomitant use increases the risk of anti-muscarinic adverse effects.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">BNF 74, 2017</a>]</p><!-- end field 9d4751fe-b5ed-431c-9437-a83f00db646c --><!-- end item 73337f47-d373-4dcc-aac4-a83f00db5f82 -->","subChapters":[]},{"id":"4dccc6d1-7218-5bf6-9cfb-48d86a9d97d9","slug":"dosing-information","fullItemName":"Dosing information","depth":3,"htmlHeader":"<!-- begin field b8f32bde-540c-4488-b80d-a83c01878c92 --><h3>Dosing information</h3><!-- end field b8f32bde-540c-4488-b80d-a83c01878c92 -->","summary":"","htmlStringContent":"<!-- begin item acbbf059-063f-414f-baf7-a83c018787c5 --><!-- begin field 364c98f1-5fda-4132-ab1f-a83c01878c92 --><h4><strong>Chlorphenamine</strong></h4><ul><li><strong>For Child 1 to 23 months</strong> — 1 mg twice daily.</li><li><strong>For Child 2 to 5 years </strong>— 1 mg every 4 to 6 hours; maximum 6 mg per day.</li><li><strong>For Child 6 to 11 years </strong>— 2 mg every 4 to 6 hours; maximum 12 mg per day.</li><li><strong>For Child 12 to 17 years </strong>— 4 mg every 4 to 6 hours; maximum 24 mg per day.</li><li><strong>For Adult </strong>— 4 mg every 4 to 6 hours; maximum 24 mg per day.</li><li><strong>For Elderly </strong>— 4 mg every 4 to 6 hours; maximum 12 mg per day.</li></ul><h4>Hydroxyzine</h4><ul><li><strong>For Child 6 months to 5 years </strong>— 5 to 15 mg daily in divided doses, dose adjusted according to weight; maximum 2 mg/kg per day.</li><li><strong>For Child 6 to 17 years (body weight up to 40 kg) </strong>— initially 15 to 25 mg daily in divided doses, dose increased as necessary, adjusted according to weight; maximum 2 mg/kg per day.</li><li><strong>For Child 6 to 17 years (body weight 40 kg and above) </strong>— initially 15 to 25 mg daily in divided doses, increased if necessary to 50 to 100 mg daily in divided doses, dose adjusted according to weight.</li><li><strong>For Adult </strong>— initially 25 mg daily, dose to be taken at night; increased if necessary to 25 mg 3 to 4 times a day.</li><li><strong>For Elderly</strong> — initially 25 mg daily, dose to be taken at night; increased if necessary to 25 mg twice daily.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">BNF 74, 2017</a>]</p><!-- end field 364c98f1-5fda-4132-ab1f-a83c01878c92 --><!-- end item acbbf059-063f-414f-baf7-a83c018787c5 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}